Alnylam Pharmaceuticals has appointed Akshay Vaishnaw to the newly created position of chief medical officer.
Vaishnaw was previously senior vice president of clinical research at Alnylam. Before that, he was senior director of translational medicine at Biogen Idec.
Mirna Therapeutics has appointed Art Krieg as a scientific advisor.
Krieg is currently an entrepreneur in residence at venture capital firm Atlas Ventures. Before this, he served as CSO of Pfizer's oligonucleotide therapeutics unit, which was recently shut down as part of a corporate restructuring.
He was also the CSO and co-founder of Coley Pharmaceuticals, which was acquired by Pfizer in 2008.